Publications by authors named "Trina Wang"
Leuk Lymphoma
January 2019
Article Synopsis
- * The treatment was generally well tolerated, though respiratory infections occurred frequently, with almost 20% requiring hospitalization, and some patients experienced manageable blood-related side effects.
- * Results showed a 50% overall response rate but limited durable outcomes, with a median progression-free survival of 8.5 months and an overall survival of 34.8 months, suggesting that this combination may not be more beneficial than using ofatumumab alone
